Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Better than a sudoku: could this drug be the key to preventing Alzheimer’s?

  • In News
  • November 29, 2021
  • Samantha Freidin
Better than a sudoku: could this drug be the key to preventing Alzheimer’s?

Our minds can be our greatest asset and our biggest enemy. The same humans that built aeroplanes, rockets and the internet are just as prone to ailments like depression, anxiety and functional cognitive decline.

Unfortunately when it comes to cognition, doing the odd sudoku probably won’t cut it if you’re hoping to maintain your current level as you age. Scientists have been poking and prodding the minds of test subjects for years to determine what we can do to preserve our brain function whilst we age.

Aside from the obvious- stimulate your brain, eat well, exercise regularly etc etc, companies like Actinogen (ASX: ACW) are exploring a pharmacological approach to the preservation of cognition.

The Company has today announced that they have reached their target enrollment of participants in their latest clinical trial for their drug, XanaMIA.

The biotech company is investigating new therapies for neurological diseases that arise from or are associated with dysregulated brain cortisol levels due to the strong association with cortisol levels in the brain and cognitive function. XanaMIA is a drug with the Company’s lead asset, Xanamem which they are hoping to develop for use in Alzheimer’s Disease, amongst others.

105 participants between the ages of 50 and 80 years old will be subjected to various doses or placebo for six weeks to determine the minimum effective dose to see improvement in cognition.

To test for cognitive function the study will use the Cogstate Neuropsychological Test Battery and the Digit Symbol Substitution Test. The Cogstate Battery is a test that is able to provide a reliable and sensitive assessment of cognitive function across various indications. The Digit Symbol Substitution Test evaluates motor speed, attention, manual dexterity and visuospatial processing. This test has been recognised previously by the FDA and other authorities as an appropriate measure for a cognitive marketing claim.

CEO and Managing Director of Actinogen, Dr. Steven Gourlay said: “The completion of XanaMIA Part A enrollment is a significant milestone in the Company’s program to evaluate its lead molecule, Xanamem, for Alzheimer’s Disease, Fragile X Syndrome and Depression. We look forward to the XanaMIA trial’s confirmation of the effects of Xanamem on working memory and other measures of cognitive ability in Q2 CY2022.”

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • actinogen
  • acw
  • alzheimers
  • asx acw
  • biotech
  • pharmaceuticals
  • steven gourlay
  • xanamem
  • xanamia
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.